vTv Therapeutics Inc.
VTVTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M | $6.4M |
| Operating income | −$32.8M | −$24.2M | −$25.5M | −$22.5M | −$21.7M | −$11.9M |
| Net income | −$27.0M | −$18.5M | −$20.3M | −$19.2M | −$13.0M | −$8.5M |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M | $14.8M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M | $11.0M |
| Equity | $64.4M | $12.2M | −$24.7M | −$10.7M | −$9.7M | −$80.1M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | — | — | — | — | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −41.9%
- Return on assets
- −30.0%
- Return on capital (ROCE)
- −39.4%
- Liabilities / assets
- 28.3%
- Debt / equity
- 0.40×
- Book value / share
- —
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.57distress
- Accruals / assets
- −1.9%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-09Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
- Phase 2Not Yet Recruitingreadout ~2027-04Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Millennium Management LlcPassive (13G)Apr 16, 2026
- Samsara Biocapital, L.P.Activist (13D)Dec 9, 2025
- Invus Global Management, LlcPassive (13G)Nov 12, 2025
- Trails Edge Capital Partners, LpPassive (13G)Sep 8, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Akkaraju SrinivasDirector | Sep 22, 2025 | Grant | 106,000 | $15.27 |
| Baker Bros. Advisors LpDirector | Sep 3, 2025 | Grant | 4,308 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 144,573 | 3.6 | +5.6% |
| Apr 30, 2026 | 136,961 | 1.9 | +21.5% |
| Apr 15, 2026 | 112,740 | 2.1 | +37.1% |
| Mar 31, 2026 | 82,236 | 1.8 | +24.6% |
| Mar 13, 2026 | 65,987 | 1.0 | +15.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 13, 2026
- Results of operationsMay 13, 2026
- Regulation FD disclosureMar 10, 2026
- Results of operationsMar 10, 2026
- Regulation FD disclosureFeb 26, 2026
- Entered a material agreementFeb 2, 2026
- Amended charter or bylawsDec 19, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.